Evidence map›Paper›PMID 36233135›Full record

ArticleInternational journal of molecular sciences2022

Amelie Taschereau, Véronique Desgagné, Sabrina Faleschini, Renée Guérin, Catherine Allard, Patrice Perron, Marie-France Hivert, Luigi Bouchard

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Amelie TaschereauDepartment of Biochemistry and Functional Genomics, Faculty of Medicine and Health Sciences (FMHS), Université de Sherbrooke, Sherbrooke, QC J1K 2R1, Canada.ORCID 0000-0001-8046-1322
Véronique DesgagnéDepartment of Biochemistry and Functional Genomics, Faculty of Medicine and Health Sciences (FMHS), Université de Sherbrooke, Sherbrooke, QC J1K 2R1, Canada.
Sabrina FaleschiniDépartement D'études sur L'enseignement et L'apprentissage, Faculté des Sciences de L'éducation, Université Laval, Québec, QC G1V 0A6, Canada.
Renée GuérinDepartment of Biochemistry and Functional Genomics, Faculty of Medicine and Health Sciences (FMHS), Université de Sherbrooke, Sherbrooke, QC J1K 2R1, Canada.
Catherine AllardCentre de Recherche du Centre Hospitalier Universitaire de Sherbrooke, Universitaire de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.ORCID 0000-0002-8829-4984
Patrice PerronCentre de Recherche du Centre Hospitalier Universitaire de Sherbrooke, Universitaire de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.
Marie-France HivertDepartment of Population Medicine, Harvard Pilgrim Health Care Institute, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0001-7752-2585
Luigi BouchardDepartment of Biochemistry and Functional Genomics, Faculty of Medicine and Health Sciences (FMHS), Université de Sherbrooke, Sherbrooke, QC J1K 2R1, Canada.
Université de Sherbrooke · CACentre Hospitalier Universitaire de Sherbrooke · CAHarvard University · USUniversité Laval · CA

Funding

CIHR IGH-155183CIHR MOP 115071Diabetes Canada OG-3-08-2622-JAFonds de Recherche du Québec - Santé 20697
6 · The paper itself

Abstract

Plasminogen activator inhibitor (PAI-1) expression has been associated with a higher risk of development of obesity. DNA methylation (DNAm) is an epigenetic mechanism regulating gene transcription and likely involved in the fetal programming of childhood obesity. Our study aimed to assess the associations between PAI-1 gene (SERPINE1) DNAm, plasma PAI-1 levels, and adiposity at five years of age. We analyzed DNAm and anthropometric data from 146 girls and 177 boys from the Gen3G prospective birth cohort. We assessed adiposity using BMI z-scores, waist circumference, total skinfolds, and percentages of total, android, and trunk fat measured by dual-energy radiography (DXA). We estimated blood cell DNAm levels at 15 CpG sites within SERPINE1 using the methylationEPIC array. After correction for multiple testing, we found that lower DNAm in SERPINE1 intron 3 (cg11353706) was associated with greater adiposity levels in girls (waist circumference: r = −0.258, p = 0.002; skinfolds: r = −0.212, p = 0. 013; android fat: r = −0.215, p = 0.015; BMI z-score: r = −0.278, p < 0.001) and that lower DNAm in the SERPINE1 promoter (cg19722814) was associated with higher plasma PAI-1 levels in boys (r = −0.178, p = 0.021). Our study suggests that DNAm levels at the SERPINE1 gene locus are negatively correlated with adiposity, but not with plasma PAI-1 levels, in young girls only.

Indexed as

AdiposityPediatric ObesityPlasminogen Activator Inhibitor 1Blood CellsBody Mass IndexChild, PreschoolDNA MethylationFemaleHumansMaleProspective StudiesPlasminogen Activator Inhibitor 1SERPINE1 protein, humanchildhoodepigeneticsobesityPAI-1

Identifiers

PMID36233135
PMCPMC9569956
OpenAlexW4303699269

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.